VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
TCMDTactile Systems Technology, Inc.
$26.62$600M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksTCMDP/E History

TCMD logoTactile Systems Technology, Inc. (TCMD) P/E Ratio History

Undervalued

Trading at 32.5x vs 5Y avg 101.4x · 50th percentile · Below historical baseline · Data 2016–2026

Current P/E (TTM)
32.5x
-68% vs 5Y avg
5Y Avg P/E
101.4x
Median 34.9x
5Y Percentile
50th
Mid-range
PEG Ratio
N/A
5-Year P/E Range
32.5x
Min8.7xMedian34.9xMax919.9x
TTM EPS$0.90
Price$26.62
Earnings Yield3.08%
EPS Growth (1Y)17.1%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Tactile Systems Technology, Inc. (TCMD) trades at a price-to-earnings ratio of 32.5x, with a stock price of $26.62 and trailing twelve-month earnings per share of $0.90.

The current P/E is 68% below its 5-year average of 101.4x. Over the past five years, TCMD's P/E has ranged from a low of 8.7x to a high of 919.9x, placing the current valuation at the 50th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, TCMD trades at a 47% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, TCMD commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TCMD DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

TCMD Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
32.5vs22.1
+47%
Above Sector
vs. S&P 500
32.5vs24.4
+33%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 17% EPS growth (1Y)

TCMD P/E vs Peers

Respiratory and sleep therapy devices peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
LNTH logoLNTHLantheus Holdings, Inc.
$7B30.5--22%
ITGR logoITGRInteger Holdings Corporation
$3B31.57.15-15%
MMSI logoMMSIMerit Medical Systems, Inc.
$4B31.6-+5%
CNMD logoCNMDCONMED Corporation
$1B21.60.59-65%
ABT logoABTAbbott Laboratories
$154B11.6Lowest0.39Best+134%Best
MDT logoMDTMedtronic plc
$102B22.0-+31%
BSX logoBSXBoston Scientific Corporation
$67B23.3-+55%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

TCMD Historical P/E Data (2016–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$26.13$0.8829.7x-73%
FY2025 Q4Dec 31 2025$29.00$0.8334.9x-68%
FY2025 Q3-$13.84$0.7718.0x-84%
FY2025 Q2Jun 30 2025$10.14$0.6216.4x-85%
FY2025 Q1Mar 31 2025$13.22$0.6620.0x-82%
FY2024 Q4-$17.13$0.7024.5x-78%
FY2024 Q3Sep 30 2024$14.61$0.6522.5x-79%
FY2024 Q2Jun 30 2024$11.94$1.388.7x-92%
FY2024 Q1Mar 31 2024$16.25$1.2013.6x-88%
FY2023 Q4Dec 31 2023$14.30$1.2011.9x-89%
FY2023 Q3Sep 30 2023$14.05$1.0813.0x-88%
FY2023 Q2Jun 30 2023$24.93$0.03919.9x+741%
FY2021 Q3-$44.45$0.39114.0x+4%
FY2021 Q2Jun 30 2021$52.00$0.6876.5x-30%
FY2020 Q1-$40.16$0.4198.0x-10%
FY2019 Q4-$67.51$0.56120.6x+10%
FY2019 Q3Sep 30 2019$42.32$0.4692.0x-16%
FY2019 Q2Jun 30 2019$56.92$0.43132.4x+21%
FY2019 Q1Mar 31 2019$52.72$0.42125.5x+15%
FY2018 Q4Dec 31 2018$45.55$0.34135.1x+24%
FY2018 Q3Sep 30 2018$71.05$0.34210.7x+93%
FY2018 Q2Jun 30 2018$52.00$0.32163.9x+50%
FY2018 Q1Mar 31 2018$31.80$0.3982.1x-25%
FY2017 Q4Dec 31 2017$28.98$0.3096.3x-12%
FY2017 Q3Sep 30 2017$30.95$0.3296.4x-12%
FY2017 Q2Jun 30 2017$28.58$0.2999.9x-9%
FY2017 Q1Mar 31 2017$18.95$0.15130.3x+19%
FY2016 Q4Dec 31 2016$16.41$0.16101.9x-7%
FY2016 Q3Sep 30 2016$18.70$0.12162.0x+48%

Average P/E for displayed period: 109.3x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TCMD — Frequently Asked Questions

Quick answers to the most common questions about buying TCMD stock.

What is TCMD's P/E ratio?

Tactile Systems Technology, Inc. (TCMD) trailing twelve-month P/E ratio is 32.5x, based on TTM diluted EPS of $0.90. The 5-year average P/E is 101.4x and the historical range spans 8.7x to 919.9x.

Is TCMD stock overvalued or undervalued?

TCMD trades at 32.5x P/E, below its 5-year average of 101.4x. At the 50th percentile of its historical range (8.7x–919.9x), the stock is priced at a discount to its own history.

Is TCMD stock expensive?

No, TCMD is not expensive on a historical basis. The current P/E of 32.5x is below the 5-year average of 101.4x and sits at the 50th percentile of its valuation range.

What is TCMD's historical P/E range?

Over the past 5 years, TCMD's P/E ratio has ranged from 8.7x to 919.9x, with a median of 34.9x and an average of 101.4x. The current P/E of 32.5x places the stock at the 50th percentile of this range. Full historical data spans 2016–2026.

How does TCMD's P/E compare to the S&P 500?

TCMD trades at 32.5x P/E versus the S&P 500 median of 24.4x. The 33% premium to the market typically reflects higher expected earnings growth or quality.

How does TCMD's valuation compare to Healthcare peers?

Tactile Systems Technology, Inc. P/E of 32.5x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is TCMD's PEG ratio?

TCMD PEG ratio is N/A, based on a P/E of 32.5x and EPS growth of 17.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is TCMD's earnings yield?

TCMD earnings yield is 3.08%, the inverse of its 32.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

TCMD P/E Ratio History (2016–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current29.7x
Period Avg101.4x
Range8.7x - 919.9x
Change-78%
20 quartersDec 31, 2018 - Mar 31, 2026